title: Targeting Triple Negative Breast Cancer with a Small-sized Paramagnetic Nanoparticle.
abstract: There is no available targeted therapy or imaging agent for triple negative breast cancer (TNBC). We developed a small-sized dendrimer-based nanoparticle containing a clinical relevant MRI contrast agent, GdDOTA and a NIR fluorescent dye, DL680. Systemic delivery of dual-modal nanoparticles led to accumulation of the agents in a flank mouse model of TNBC that were detected by both optical and MR imaging.In-vivofluorescence images, as well asex-vivofluorescence images of individual organs, demonstrated that nanoparticles accumulated into tumor selectively. A dual modal strategy resulted in a selective delivery of a small-sized (GdDOTA)42-G4-DL680 dendrimeric agent to TNBC tumors, avoiding other major organs.
authors.affiliation: Department of Neurology, Henry Ford Hospital, Detroit, MI 48202, USA.
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Department of Neurology, Henry Ford Hospital, Detroit, MI 48202, USA.
authors.forename: Nadimpalli Rs
authors.initials: NR
authors.lastname: Varma
authors.affiliation: Department of Neurology, Henry Ford Hospital, Detroit, MI 48202, USA.
authors.forename: Zhang Z
authors.initials: ZZ
authors.lastname: Gang
authors.affiliation: Department of Neurology, Henry Ford Hospital, Detroit, MI 48202, USA.
authors.forename: James R
authors.initials: JR
authors.lastname: Ewing
authors.affiliation: Tumor Angiogenesis Laboratory, Georgia Cancer Center, Augusta University, Augusta, GA, USA.
authors.forename: Ali S
authors.initials: AS
authors.lastname: Arbab
authors.affiliation: Department of Neurology, Henry Ford Hospital, Detroit, MI 48202, USA.
authors.forename: Meser M
authors.initials: MM
authors.lastname: Ali
keywords: Dual modality; MRI; Optical imaging; Triple negative breast cancer